Separation of delta6- and delta9,11-estradiol: analytical method development, validation and practical application

Area of Science:

• Analytical Chemistry
• Pharmaceutical Analysis

Background:

• Estradiol (E2) degradation products, particularly delta6- and delta9,11-E2, pose separation challenges due to structural similarity.
• Existing literature lacks adequate methods for resolving these closely related compounds.

Purpose of the Study:

• To develop and validate a High-Performance Liquid Chromatography (HPLC) method for the separation and quantitation of estradiol (E2) and its key degradation products.
• To establish a reliable analytical technique for assessing the stability and quality of E2-containing pharmaceutical formulations.

Main Methods:

• Utilized a Kinetex PFP analytical column with a mobile phase of methanol and deionized water.
• Employed both UV and fluorescence detection modes to achieve maximal sensitivity and specificity.
• Demonstrated method applicability using Vagifem tablets and conducted full validation (selectivity, sensitivity, linearity, precision, accuracy).

Main Results:

• Successfully separated estradiol (E2) from its structurally similar degradation products, including delta6-E2 and delta9,11-E2.
• Achieved maximal sensitivity and specificity through optimized UV and fluorescence detection.
• Validated the HPLC method, confirming its reliability for pharmaceutical analysis.

Conclusions:

• The developed HPLC method effectively separates and quantitates estradiol (E2) and its degradation products.
• This validated method provides a robust tool for quality control of estradiol formulations like Vagifem tablets.
• Addresses a critical gap in analytical methodology for steroid stability assessment.